Compare Keurig Dr Pepper Inc. Common Stock (KDP) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keurig Dr Pepper Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Keurig Dr Pepper Inc. Common Stock trades at $33.5 (market cap $45.07B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Keurig Dr Pepper Inc. Common Stock pays a 2.78% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keurig Dr Pepper Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| KDP | NTRA | |
|---|---|---|
Market Cap | $45.07B | $57.03B |
Volume | 9,868,301 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $33.50 | $425.64 |
52-Week Low | $25.31 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $73.53B | $56.18B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keurig Dr Pepper (KDP) trades at $32.66, down 0.27% today, with strong technical momentum showing bullish moving averages and key support at $32. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.57 beating expectations of $0.537, and maintains a healthy 49.39% gross margin. Recent news highlights the planned 2027 business split and beverage innovation pipeline as growth catalysts.
KDP presents a favorable investment case with 62% analyst buy ratings and a $37.75 consensus price target offering 15% upside. However, risks include elevated debt levels at 74.2% of market cap and potential execution challenges with the upcoming corporate restructuring. The stock's current valuation at 32.99 P/E requires continued earnings growth to justify further appreciation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keurig Dr Pepper Inc. Common Stock
Keurig Dr Pepper produces and distributes coffee, soft drinks, juices, and other beverages. It also operates the Keurig single-serve coffee system.
Read more on KDP →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
